Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHIEF-PD rivastigmine fall prevention trial in Parkinson's disease
2018-003219-23Phase 3Unknown
- Sponsor
- University of Bristol
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Rivastigmine transdermal patch with Placebo patch (2 arms). Primary endpoint: Fall rate over 12 months. Status: unknown.
02
Drugs
rivastigmine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-003219-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003219-23.